Overview

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

Status:
Completed

Trial end date:
2005-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Solifenacin Succinate
Tolterodine Tartrate